Navigation Links
ClinStar, LLC Establishes New Office on the US East Coast
Date:7/19/2011

SAN FRANCISCO, July 19, 2011 /PRNewswire/ -- ClinStar, LLC, an established CRO providing clinical research services in the emerging markets of Russia and Eastern Europe to the pharmaceutical and biotechnology industry, announced today the opening of a new regional office on the East Coast of the United States.

(Photo:  http://photos.prnewswire.com/prnh/20110719/SF36975LOGO)

As a second US location to its headquarters in San Francisco, CA, ClinStar's new office is located at 1000 Park Forty Plaza, Durham, NC. In addition to offering adequate space to centralize ClinStar's regional workforce, the new facility was chosen in large part because of its flexibility to accommodate the company's future growth.

According to President and CEO David Passov, "This is the realization of a major long-term business goal for ClinStar. Our new office further solidifies our commitment to offer our clients the local expertise and knowledge they need to successfully conduct clinical trials in Russia and Eastern Europe while ensuring our business operates in accordance with the proven business and management principles practiced in the West."  

"We are thrilled with the opening of our new office," says Erin King, Executive Director Business Development and Marketing. This move is just one of several important initiatives positioning ClinStar as the leading provider of clinical research services in Russia, Ukraine and parts of Eastern Europe. Our new facility affords not only centralized office space for our employees, but also upscale conference space for hosting meetings with our customers."  

About ClinStar, LLC

ClinStar is one of the most prominent CROs in the emerging markets of Eastern Europe and the Baltics, with more than 10 years of expertise in Phase I-IV clinical studies in multiple therapeutic areas. Headquartered in San Francisco, California, ClinStar manages studies from its offices in Russia, Ukraine and Belarus with total staff of over 300 people. Its portfolio contains over 130 clinical trials conducted for US and European pharmaceutical and biotechnology companies. More information is available at www.clinstar.com.


'/>"/>
SOURCE ClinStar, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Medicare Contractor Establishes Reimbursement Coding Guidance for Monograms Trofile Assay
2. Transgenomic Establishes Collaboration With the National Cancer Institute to Investigate Mitochondrial Genome and Associated Nuclear Genes in Cancer Cell Lines
3. Pharmaxis Establishes Named Patient Program for Bronchitol
4. First Candidate from Esperances Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept
5. BD Establishes $1.2 Million Fund for Haiti Earthquake Relief Efforts
6. FUJIFILM Establishes Medical Informatics Organization
7. Renhuang Appoints New Director and Establishes Nominating and Compensation Committee
8. Mach 7 Technologies Establishes New Headquarters in Burlington, VT
9. Pfenex Inc. Establishes Reagent Protein Distribution Agreement With Cedarlane Corporation
10. HUYA Biosciences Establishes Strategic Partnership with Sun Yat-sen Universitys School of Pharmaceutical Sciences
11. Varian Medical Systems Establishes Radiotherapy Training Center in Mumbai, India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... July 20, 2017  Prime Therapeutics LLC (Prime) released this ... M.D., following today,s Institute for Clinical and Economic Review,s (ICER) ... the effectiveness and value of abuse-deterrent formulations (ADF) of opioids. ... roundtable at the meeting. ... cost benefit to the use of abuse-deterrent formulations (ADF) in ...
(Date:7/14/2017)... 2017 It should come as no surprise to ... in the midst of a crippling opioid epidemic. According to ... number of overdose deaths from opiate-based medications has quadrupled, Says, ... million dead from 2001 to 2015". During this time, the ... similarly quadrupled, drawing a compelling link between prescription and eventual ...
(Date:7/12/2017)... INDIANAPOLIS , July 12, 2017  Eli Lilly and ... settlement agreement with generic companies to resolve pending patent litigation ... Virginia regarding the Cialis ® ... expire on April 26, 2020. As part of the agreement, ... on September 27, 2018. "The unit dose patent ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... July 24, 2017 , ... Axiad IDS , a ... it has partnered with WALLIX to expand its solution to help government ... There are a number of ways to address the authentication requirements within NIST ...
(Date:7/24/2017)... Solana Beach, California (PRWEB) , ... July 24, ... ... and commercialization of autologous fat (adipose) transfer systems announces the issuance of United ... (the ‘324 patent) for its adipose filtration technology. The '398 and '324 ...
(Date:7/24/2017)... Georgia (PRWEB) , ... July 24, 2017 , ... ... comprehensive sleep management solution focused on delivering end-to-end sleep health care ... program. , Recent literature shows that adherence rates for positive airway pressure (PAP) ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... ... today CURE announced that they have enrolled over 100,000 children in their treatment ... children born every year in areas where treatment is limited or non-existent. Without ...
(Date:7/24/2017)... Binzhou, Shandong Province (PRWEB) , ... July 24, ... ... Traditional Chinese Medicine's "Chinese Medicine Clinical Vitiligo Hospital" was set up, and the ... State Administration of traditional Chinese medicine, the head of the army's health system, ...
Breaking Medicine News(10 mins):